CDEK
← All organizations

Hoechst Marion Roussel

For profitContributed to NME
Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 2

First clinical trial

Nov 2, 1999

First marketed drug

Jan 1, 1995

First NDA

Jun 22, 1998

Last known activity

Nov 2, 1999

Acquired by Aventis → Sanofi-Synthelabo → Sanofi-Aventis on Jan 1, 1999

Timeline

1990s

  1. Jan 1, 1995

    Hoechst Marion Roussel— Founded

  2. Jan 1, 1995

    Hoechst— Acquired

  3. Jan 1, 1995

    Marion Merrell Dow— Acquired

  4. Jun 22, 1998

    rifapentine— NDA Organization

  5. Jan 1, 1999

    Aventis— Acquired By

2000s

  1. Jan 1, 2004

    Sanofi-Aventis— Now

Drugs by trial phase (12 distinct, 7 trials)

Phase 1 (1 own, 0 via acquisition)

Other trials (4 own, 0 via acquisition)

Indications

Approved for

Studied for

Marketed drugs (2)

Subsidiaries (2 direct, 7 total across the full acquisition tree)

Recent trials (7)

Details

Founded
Frankfurt, DE Jan 1, 1995
First NDA
Jun 22, 1998
Last known activity
Nov 2, 1999

Designations held

  • Orphan drug
  • Priority review
  • Accelerated approval

Notes

formed through merger of Hoechst with Cassella AG, Roussel Uclaf and Marion Merrell Dow